Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study

Blood (2025) 146 (Supplement 1): 2778.

https://doi.org/10.1182/blood-2025-2778

Published: 2025

Journal Articles

Phase II study of lenalidomide in combination with rituximab, cyclophosphadmie, doxorubicin, vincristine, and prenisone (R-CHOP) for central nervous system prophylaxis in high-risk diffuse large B cell lymphoma

Hyungwoo Cho, Jaewon Hyung, Hyeon-Seok Eom, Sung-Nam Lim, Hye Jin Kang, Myung-Won Lee, Young Rok Do, Seong Hyun Jeong, Hyo Jung Kim, Youngil Koh, Seong Yoon Yi, Ka-Won Kang, Min Kyoung Kim, Jae-Yong Kwak, Gyeong-Won Lee, Dok Hyun Yoon

Blood (2025) 146 (Supplement 1): 1915.

https://doi.org/10.1182/blood-2025-1915

Published: 2025

Journal Articles

Phase I/II study of zanubrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (ZR-ICE) in Relapsed/Refractory diffuse large B-cell lymphoma: Results of the Phase I portion

Hyungwoo Cho, Jaewon Hyung, Dong Won Baek, Ho Sup Lee, Hye Jin Kang, Gyeong-Won Lee, Jeong-Ok Lee, Myung-Won Lee, Sung-Nam Lim, Sung Yong Oh, Ho-Jin Shin, Kwai Han Yoo, Young Rok Do, Jae-Yong Kwak, Yong-pyo Lee, Deok-Hwan Yang, Dok Hyun Yoon

Blood (2025) 146 (Supplement 1): 3702.

https://doi.org/10.1182/blood-2025-3702

Published: 2025

Journal Articles

Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response

Sewon Lee, Yeung-Chul Mun, Hongtae Kim, Sung-Ho Park, Semin Lee, Seunghoon Kim, Sung-Hyun Kim, Young Rok Do, Soo-Hyun Kim, Kyung-Mi Kee, Sahee Park, Dong-Wook Kim

Blood (2025) 146 (Supplement 1): 2002.

https://doi.org/10.1182/blood-2025-2002

Published: 2025

Journal Articles

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Blood (2024) 144 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2024-202823

Published: 2024

Journal Articles

Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Blood (2024) 144 (Supplement 1): 4501.

https://doi.org/10.1182/blood-2024-199281

Published: 2024

Journal Articles

Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 4296.

https://doi.org/10.1182/blood-2024-205069

Published: 2024

Journal Articles

Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial

Yasmin H. Karimi, Michael Roost Clausen, David John Lewis, Wojciech Jurczak, Michelle Poon, Tae Min Kim, Young Rok Do, Pieternella Lugtenburg, Kristin Conte, David Soong, Barbara D'Angelo Månsson, Zhu Li, Christian Eskelund, Martin Hutchings

Blood (2024) 144 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2024-199225

Published: 2024

Journal Articles

Clinical Usefulness of Sequential Circulating-Tumor DNA Analysis in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy

Ga-Young Song, Joo Heon Park, Seung Jung Han, Ho Cheol Jang, Mihee Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Jae-Sook Ahn, Je-Jung Lee, Hyeoung-Joon Kim, Young Rok Do, Deok-Hwan Yang

Blood (2024) 144 (Supplement 1): 6221.

https://doi.org/10.1182/blood-2024-204540

Published: 2024

Journal Articles

Nationwide Analysis on Incidences and Treatment Outcomes of T-Cell Subtype Lymphomas Based on Health Insurance Review & Assessment Service

Jungmin Lee, Youngeun Jang, Yunji Lee, Hee Jeong Cho, Joon Ho Moon, Young Rok Do, Sang Kyun Sohn, Dong Won Baek

Blood (2024) 144 (Supplement 1): 6397.

https://doi.org/10.1182/blood-2024-203187

Published: 2024

Journal Articles

Novel Chip-Based Digital Real-Time PCR Platform with Lab on an Array for the Sensitive Detection of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia

Hyun-Woo Song, Sung-Hyun Kim, Young Rok Do, Kyung-Mi Ki, Soo Hyun Kim, Min-Sik Song, Seung-Shick Shin, Dong-Wook Kim

Blood (2024) 144 (Supplement 1): 6596.

https://doi.org/10.1182/blood-2024-206252

Published: 2024

Journal Articles

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Blood (2024) 144 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2024-205164

Published: 2024

Journal Articles

A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Sewon Lee, Yeung-Chul Mun, Hongtae Kim, Sung-Ho Park, Semin Lee, Seunghoon Kim, Sung-Hyun Kim, Young Rok Do, Soo-Hyun Kim, Kyung-Mi Kee, Yoonsung Lee, Dong-Wook Kim

Blood (2024) 144 (Supplement 1): 1779.

https://doi.org/10.1182/blood-2024-199242

Published: 2024

Journal Articles

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 4483.

https://doi.org/10.1182/blood-2024-200836

Published: 2024

Journal Articles

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Blood (2023) 142 (Supplement 1): 6675.

https://doi.org/10.1182/blood-2023-174439

Published: 2023

Journal Articles

Multicenter, Prospective Study to Investigate the Efficacy and Safety of Intravenous-Immunoglobulin Therapy in Elderly Patients with Diffuse Large B Cell Lymphoma Treated with R-Mini-CHOP

Dong Won Baek, Ga-Young Song, Hyukjin Choi, Ho Sup Lee, Young Rok Do, Ji Hyun Lee, Joon Ho Moon, Deok-Hwan Yang

Blood (2023) 142 (Supplement 1): 2327.

https://doi.org/10.1182/blood-2023-189114

Published: 2023

Journal Articles

Highly Sensitive Chip-Based Digital PCR Platform for Quantitative Detection of BCR::ABL1 Transcripts throughout CML Treatment

Hyun-Woo Song, Sung-Hyun Kim, Young Rok Do, Kyung-Mi Ki, Soo Hyun Kim, Min-Sik Song, Seung-Shick Shin, Dong-Wook Kim

Blood (2023) 142 (Supplement 1): 1805.

https://doi.org/10.1182/blood-2023-185162

Published: 2023

Journal Articles

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Blood (2023) 142 (Supplement 1): 6638.

https://doi.org/10.1182/blood-2023-183100

Published: 2023

Journal Articles

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2023-180499

Published: 2023

Journal Articles

Improvement of Treatment-Free Remission Rate Following Discontinuation of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Phase, Chronic Myeloid Leukemia

Sewon Lee, Hongtae Kim, Semin Lee, Seunghoon Kim, Sung-Ho Park, Sung-Hyun Kim, Young Rok Do, Soo-Hyun Kim, Kyung-Mi Kee, Dong-Wook Kim

Blood (2023) 142 (Supplement 1): 1806.

https://doi.org/10.1182/blood-2023-178408

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study

Phase II study of lenalidomide in combination with rituximab, cyclophosphadmie, doxorubicin, vincristine, and prenisone (R-CHOP) for central nervous system prophylaxis in high-risk diffuse large B cell lymphoma

Phase I/II study of zanubrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (ZR-ICE) in Relapsed/Refractory diffuse large B-cell lymphoma: Results of the Phase I portion

Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial

Clinical Usefulness of Sequential Circulating-Tumor DNA Analysis in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy

Nationwide Analysis on Incidences and Treatment Outcomes of T-Cell Subtype Lymphomas Based on Health Insurance Review & Assessment Service

Novel Chip-Based Digital Real-Time PCR Platform with Lab on an Array for the Sensitive Detection of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Multicenter, Prospective Study to Investigate the Efficacy and Safety of Intravenous-Immunoglobulin Therapy in Elderly Patients with Diffuse Large B Cell Lymphoma Treated with R-Mini-CHOP

Highly Sensitive Chip-Based Digital PCR Platform for Quantitative Detection of BCR::ABL1 Transcripts throughout CML Treatment

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Improvement of Treatment-Free Remission Rate Following Discontinuation of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Phase, Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only